1.82
price up icon1.40%   0.03
after-market アフターアワーズ: 1.82
loading
前日終値:
$1.79
開ける:
$1.81
24時間の取引高:
1.43M
Relative Volume:
0.80
時価総額:
$392.73M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-3.50
EPS:
-0.52
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-2.42%
1か月 パフォーマンス:
+32.48%
6か月 パフォーマンス:
+60.62%
1年 パフォーマンス:
+84.26%
1日の値動き範囲:
Value
$1.75
$1.83
1週間の範囲:
Value
$1.75
$1.87
52週間の値動き範囲:
Value
$0.80
$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1196)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
167
Name
Twitter
@akebiatx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

AKBA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AKBA 1.82 392.73M 194.75M -51.26M -23.38M -0.52
ZTS 176.72 79.33B 9.15B 2.43B 2.31B 4.92
HLN 9.55 43.04B 14.26B 1.55B 0 0.3327
TAK 13.32 42.13B 30.27B 1.93B 3.45B 0.444
TEVA 17.07 19.29B 16.77B -959.00M 1.37B -2.00
VTRS 13.25 15.77B 15.24B -646.50M 1.88B 1.53

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
Nov 20, 2024

Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 14, 2024

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Yahoo Finance UK

Nov 14, 2024
pulisher
Nov 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan

Nov 12, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Prepares for Vafseo Launch - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - citybiz

Nov 07, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow

Nov 07, 2024
pulisher
Nov 06, 2024

Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN

Nov 06, 2024
pulisher
Nov 04, 2024

Akebia Therapeutics to present at upcoming investor conferences - MSN

Nov 04, 2024
pulisher
Nov 02, 2024

Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz

Nov 01, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World

Oct 31, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Oct 31, 2024
pulisher
Oct 25, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 25, 2024
pulisher
Oct 23, 2024

Akebia stock climbs 8% on dialysis provider supply agreement - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

High Growth Tech Stocks to Watch in October 2024 - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St

Oct 23, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance

Oct 22, 2024
pulisher
Oct 17, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne

Oct 17, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Oct 16, 2024
pulisher
Oct 15, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan

Oct 15, 2024
pulisher
Oct 14, 2024

A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily

Oct 14, 2024
pulisher
Oct 12, 2024

Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada

Oct 12, 2024
pulisher
Oct 12, 2024

Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat

Oct 12, 2024
pulisher
Oct 12, 2024

Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India

Oct 12, 2024

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$87.32
price up icon 1.04%
$13.40
price down icon 0.30%
$85.45
price down icon 0.08%
$59.65
price up icon 1.07%
$125.00
price up icon 1.44%
$13.25
price up icon 0.99%
大文字化:     |  ボリューム (24 時間):